Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Real-time Estimate Cboe Europe  -  11:30:00 2023-02-03 am EST
1435.70 GBX   +0.58%
02:44aGsk: morgan stanley cuts target price to 1485p from 1520p…
RE
02/02GSK plc - Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
AQ
02/02GSK : Credit Suisse gives a Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK Names Burberry Executive Julie Brown New Finance Chief

09/26/2022 | 04:47am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.85% 10542 Delayed Quote.-8.63%
BURBERRY GROUP PLC 0.04% 2471 Delayed Quote.21.67%
GSK PLC 0.99% 1441.2 Delayed Quote.-0.71%
SMITH & NEPHEW PLC 3.40% 1187 Delayed Quote.3.61%
All news about GSK PLC
02:44aGsk: morgan stanley cuts target price to 1485p from 1520p…
RE
02/02GSK plc - Benlysta granted Orphan Drug Designation by US FDA for the potential treatmen..
AQ
02/02GSK : Credit Suisse gives a Neutral rating
MD
02/02GSK : Deutsche Bank reiterates its Neutral rating
MD
02/02JPMorgan Keeps GSK at Underweight, Raises PT
MT
02/02GSK : Sell rating from JP Morgan
MD
02/02Gsk : FY 2022 results transcript
PU
02/02Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in ad..
AQ
02/02Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of syste..
AQ
02/02GSK gets FDA approval for drug to treat anaemia in adults on dialysis
AN
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 105 M 35 719 M 35 719 M
Net income 2022 6 339 M 7 780 M 7 780 M
Net Debt 2022 14 349 M 17 609 M 17 609 M
P/E ratio 2022 8,60x
Yield 2022 4,27%
Capitalization 57 597 M 70 685 M 70 685 M
EV / Sales 2022 2,47x
EV / Sales 2023 2,47x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 1 427,40 GBX
Average target price 1 697,73 GBX
Spread / Average Target 18,9%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-0.71%70 685
JOHNSON & JOHNSON-6.29%432 802
ELI LILLY AND COMPANY-6.36%314 224
NOVO NORDISK A/S-3.40%300 394
ROCHE HOLDING AG-5.73%264 917
MERCK & CO., INC.-6.75%262 312